MeSH tree: D27.505.954.248
A study led by Dr. Jason Pitt, Principal Investigator at the Cancer Science Institute of Singapore (CSI Singapore), has identified eight new "signatures" of DNA patterns (gains and/or losses) in breast cancer. By analyzing ...
12 hours ago
0
4
A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly kidney cancer. In the new study, published in Cell Reports Medicine, researchers tested a novel ...
May 14, 2026
0
45
MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.
May 13, 2026
0
11
Creativity and curiosity have always been central to the work of Joshua Moreau, Ph.D., an immunologist whose work at Oregon Health & Science University sits at the intersection of harnessing the immune system; delving into ...
May 8, 2026
0
3
Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme—RNase H2—that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast ...
May 4, 2026
0
12
Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern ...
May 4, 2026
0
5
Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important defense systems is homologous recombination, a high-precision repair pathway that fixes broken DNA ...
Apr 30, 2026
0
7
Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are associated with immune-related complications that can affect the kidneys. These complications sometimes ...
Apr 22, 2026
0
4
Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced ...
Apr 21, 2026
0
4
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
